SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on December 17, 2008. The registrant is a Colorado-based biopharmaceutical company. Note: The request metadata referenced "Riot Platforms, Inc." and a 2008 date, but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance.
Material Changes and Events
- Patent Allowance: On December 17, 2008, the company received a Notice of Allowance from the Patent Office for diagnostic methods related to appendicitis.
- Regulatory Status: This event represents a significant intellectual property milestone for the company's diagnostic pipeline.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent application. The primary disclosure is the successful progression of the patent application for appendicitis diagnostic methods.
Investor Verification Checklist
- Verify the scope and commercial viability of the allowed appendicitis diagnostic methods.
- Confirm the timeline for the final issuance of the patent following the Notice of Allowance.
- Review the attached press release (Exhibit 99.1) for specific details on the patent claims.
- Check subsequent filings for any financial impact or strategic shifts resulting from this IP milestone.